March 27, 2013 at 09:34 AM EDT
Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-2018---New-product-entries-in-both-niche-and-broader-Parkinson's-disease-treatment-will-boost-market-despite-patent-cliff.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff". A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer's disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. The market for Parkinson's disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, and key M&A and licensing deal trends in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Huntington's Disease (HD).

- The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

- Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan.

- Key market drivers and barriers

- The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and is also provided.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Understand the competitive environment for Neurodegenerative Diseases

- Understand the clinical and commercial impact of major patent expiries in the neurodegenerative diseases markets

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the neurodegenerative diseases market in the forecast period

- Grasp the unmet need which exists in the neurodegenerative diseases Market

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

Table of Contents

1 Table of Contents 6

1.1 List of Tables 9

1.2 List of Figures 11

2 Neurodegenerative Diseases Market to 2018: Introduction 13

3 Neurodegenerative Diseases Market to 2018: Global Market Overview 14

3.1 Revenue 14

3.2 Treatment Usage Pattern 16

3.3 Distribution by Market 17

3.4 Drivers and Restraints of the Neurodegenerative Diseases Market 18

3.4.1 Drivers 18

3.4.2 Restraints 18

4 Therapeutic Landscape 19

4.1 Market for Alzheimer's Disease 19

4.1.1 Introduction 19

4.1.2 Revenue and Forecasts 21

4.1.3 Treatment Usage Pattern 23

4.1.4 Geographical Landscape 24

4.1.5 Drivers and Restraints for the Alzheimer's Disease Market 46

4.2 Market for Parkinson's Disease 47

4.2.1 Introduction 47

4.2.2 Revenue and Forecasts 49

4.2.3 Treatment Usage Pattern 50

4.2.4 Geographical Landscape 51

4.2.5 Drivers and Restraints for the Parkinson's Disease Market 73

4.3 Market for Amyotrophic Lateral Sclerosis 74

4.3.1 Introduction 74

4.3.2 Revenue and Forecasts 76

4.3.3 Treatment Usage Pattern 77

4.3.4 Geographical Landscape 78

4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market 100

4.4 Market for Huntington's Disease 101

4.4.1 Introduction 101

4.4.2 Revenue and Forecasts 103

4.4.3 Treatment Usage Pattern 104

4.4.4 Geographical Landscape 105

4.4.5 Drivers and Restraints for the Huntington's Disease Market 127

5 Neurodegenerative Diseases Market: Pipeline Analysis 128

5.1 Introduction 128

5.2 Summary of the Current Neurodegenerative Diseases R&D Pipeline 129

5.2.1 Alzheimer's Disease 129

5.2.2 Amyotrophic Lateral Sclerosis 142

5.2.3 Parkinson's Disease 147

5.2.4 Huntington's Disease 155

6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations 158

6.1 Merger and Acquisition Deals 158

6.1.1 Sanofi-Synthelabo Merges with Aventis 160

6.1.2 Bayer Acquires Schering 160

6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m 160

6.1.4 Teva Pharma Acquires Ivax 160

6.1.5 Abbott Labs Acquires Solvay Pharma 160

6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion 160

6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma 161

6.1.8 Biovail Acquires Valeant Pharma 161

6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion 161

6.1.10 Merck Acquires Banyu Pharma 161

6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion 161

6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma 161

6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon 162

6.1.14 Lundbeck Acquires Ovation Pharma 162

6.1.15 Eli Lilly and Company Acquires Avid RadioPharma 162

6.1.16 Abbott Labs Completes Acquisition of Facet Biotech 162

6.1.17 Biogen Idec Acquires Fumapharm 162

6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m 163

6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma 163

6.1.20 Pfizer Acquires Rinat Neuroscience 163

6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m 163

6.1.22 Biogen Idec Acquires Panima Pharma 164

6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey 164

6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical 164

6.1.25 MGI PHARMA Acquires Guilford Pharma 164

6.1.26 H. Lundbeck Acquires LifeHealth 164

6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma 165

6.1.28 EPIX Pharma Acquires Predix Pharma 165

6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals 165

6.1.30 Biotie Therapies Acquires Synosia Therapeutics 165

6.2 Licensing Agreements 166

6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine 167

6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck 167

6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors 167

6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118 167

6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS 168

6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics 168

6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly 168

6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies 168

6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals 168

6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 169

6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept 169

6.2.12 AC Immune Enters into Licensing Agreement with Genentech 169

6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs 169

6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology 170

6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide 170

6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics 170

6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066 170

6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole 171

6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono 171

6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck & Co 171

6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma 171

6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma 171

6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma 172

6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis 172

6.3 Co-Development Deals 173

6.3.1 GlaxoSmithKline Signs an Agreement with Targacept 174

6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma 174

6.3.3 Evotec Enters into Co-Development Agreement with Roche 174

6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon 174

6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck & Co 174

6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca 175

6.3.7 Boehringer Ingelheim Partners with Vitae Pharma 175

6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics 175

6.3.9 Ceregene Enters into Agreement with Genzyme 175

7 Appendix 176

7.1 Market Definitions 176

7.2 Abbreviations 176

7.3 Sources 177

7.4 Research Methodology 179

7.4.1 Coverage 180

7.4.2 Secondary Research 180

7.4.3 Primary Research 180

7.5 Therapeutic Landscape 181

7.5.1 Epidemiology-based Forecasting 181

7.5.2 Market Size by Geography 182

7.6 Geographical Landscape 183

7.7 Pipeline Analysis 184

7.8 Competitive Landscape 184

7.8.1 Expert Panel Validation 184

7.9 Contact Us 184

7.10 Disclaimer 184

List of Tables

Table 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012–2018 14

Table 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012–2018 15

Table 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern ('000), 2012–2018 16

Table 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market ($m), 2012–2018 17

Table 5: Alzheimer's Disease Market, Global, Revenue Forecast ($m), 2012–2018 22

Table 6: Alzheimer's Disease Market, Global, Treatment Usage Pattern ('000), 2012–2018 23

Table 7: Alzheimer's Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018 24

Table 8: Alzheimer's Disease Market, Global, Revenue Forecast ($m), 2012–2018 25

Table 9: Alzheimer's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 26

Table 10: Alzheimer's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 27

Table 11: Alzheimer's Disease Market, UK, Revenue Forecast ($m), 2012–2018 28

Table 12: Alzheimer's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 29

Table 13: Alzheimer's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 30

Table 14: Alzheimer's Disease Market, Global, Revenue Forecast ($m), 2012–2018 31

Table 15: Alzheimer's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 32

Table 16: Alzheimer's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 33

Table 17: Alzheimer's Disease Market, Germany, Revenue Forecast ($m), 2012–2018 34

Table 18: Alzheimer's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 35

Table 19: Alzheimer's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 36

Table 20: Alzheimer's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 37

Table 21: Alzheimer's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 38

Table 22: Alzheimer's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 39

Table 23: Alzheimer's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 40

Table 24: Alzheimer's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 41

Table 25: Alzheimer's Disease Market, Spain, Treatment Usage Pattern ('000), 2012–2018 42

Table 26: Alzheimer's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 43

Table 27: Alzheimer's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 44

Table 28: Alzheimer's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 45

Table 29: Parkinson's Disease Market, Global, Revenue Forecast ($m), 2012–2018 49

Table 30: Parkinson's Disease Market, Global, Treatment Usage Pattern ('000), 2012–2018 50

Table 31: Parkinson's Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018 51

Table 32: Parkinson's Disease Market, US, Revenue Forecast ($m), 2012–2018 52

Table 33: Parkinson's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 53

Table 34: Parkinson's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 54

Table 35: Parkinson's Disease Market, UK, Revenue Forecast ($m), 2012–2018 55

Table 36: Parkinson's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 56

Table 37: Parkinson's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 57

Table 38: Parkinson's Disease Market, France, Revenue Forecast ($m), 2012–2018 58

Table 39: Parkinson's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 59

Table 40: Parkinson's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 60

Table 41: Parkinson's Disease Market, Germany, Revenue Forecast ($m), 2012–2018 61

Table 42: Parkinson's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 62

Table 43: Parkinson's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 63

Table 44: Parkinson's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 64

Table 45: Parkinson's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 65

Table 46: Parkinson's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 66

Table 47: Parkinson's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 67

Table 48: Parkinson's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 68

Table 49: Parkinson's Disease Market, Spain, Treatment Usage Pattern Forecast ('000), 2012–2018 69

Table 50: Parkinson's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 70

Table 51: Parkinson's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 71

Table 52: Parkinson's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 72

Table 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012–2018 76

Table 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern ('000), 2010–2018 77

Table 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012–2018 78

Table 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012–2018 79

Table 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012–2018 80

Table 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern ('000), 2012–2018 81

Table 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012–2018 82

Table 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012–2018 83

Table 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern ('000), 2012–2018 84

Table 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012–2018 85

Table 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012–2018 86

Table 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern ('000), 2012–2018 87

Table 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012–2018 88

Table 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012–2018 89

Table 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern ('000), 2012–2018 90

Table 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012–2018 91

Table 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012–2018 92

Table 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern ('000), 2012–2018 93

Table 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012–2018 94

Table 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012–2018 95

Table 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern ('000), 2012–2018 96

Table 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012–2018 97

Table 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012–2018 98

Table 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern ('000), 2012–2018 99

Table 77: Huntington's Disease Market, Global, Revenue Forecast ($m), 2012–2018 103

Table 78: Huntington's Disease Market, Global, Treatment Usage Pattern ('000), 2012–2018 104

Table 79: Huntington's Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018 105

Table 80: Huntington's Disease Market, US, Revenue Forecast ($m), 2012–2018 106

Table 81: Huntington's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 107

Table 82: Huntington's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 108

Table 83: Huntington's Disease Market, UK, Revenue Forecast ($m), 2012–2018 109

Table 84: Huntington's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 110

Table 85: Huntington's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 111

Table 86: Huntington's Disease Market, France, Revenue Forecast ($m), 2012–2018 112

Table 87: Huntington's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 113

Table 88: Huntington's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 114

Table 89: Huntington's Disease Market, Germany, Revenue Forecast ($m), 2012–2018 115

Table 90: Huntington's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 116

Table 91: Huntington's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 117

Table 92: Huntington's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 118

Table 93: Huntington's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 119

Table 94: Huntington's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 120

Table 95: Huntington's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 121

Table 96: Huntington's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 122

Table 97: Huntington's Disease Market, Spain, Treatment Usage Pattern ('000), 2012–2018 123

Table 98: Huntington's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 124

Table 99: Huntington's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 125

Table 100: Huntington's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 126

Table 101: Neurodegenerative Diseases Market, Global, Alzheimer's Disease Product Pipeline, 2012 129

Table 102: Neurodegenerative Diseases Market, Global, Amyotrophic Lateral Sclerosis Product Pipeline, 2012 142

Table 103: Neurodegenerative Diseases Market, Global, Parkinson's Disease Product Pipeline, 2012 147

Table 104: Neurodegenerative Diseases Market, Global, Huntington's Disease Product Pipeline, 2012 155

List of Figures

Figure 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012–2018 14

Figure 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018 15

Figure 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern ('000), 2012–2018 16

Figure 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market (%), 2012 and 2018 17

Figure 5: Alzheimer's Disease Market, Global, Revenue Forecast ($m), 2012–2018 22

Figure 6: Alzheimer's Disease Market, Global, Treatment Usage Pattern ('000), 2012–2018 23

Figure 7: Alzheimer's Disease Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018 24

Figure 8: Alzheimer's Disease Market, US, Revenue Forecast ($m), 2012–2018 25

Figure 9: Alzheimer's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 26

Figure 10: Alzheimer's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 27

Figure 11: Alzheimer's Disease Market, UK, Revenue Forecast ($m), 2012–2018 28

Figure 12: Alzheimer's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 29

Figure 13: Alzheimer's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 30

Figure 14: Alzheimer's Disease Market, France, Revenue Forecast ($m), 2012–2018 31

Figure 15: Alzheimer's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 32

Figure 16: Alzheimer's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 33

Figure 17: Alzheimer's Disease Market, Germany, Revenue Forecast ($m), 2004–2018 34

Figure 18: Alzheimer's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 35

Figure 19: Alzheimer's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 36

Figure 20: Alzheimer's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 37

Figure 21: Alzheimer's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 38

Figure 22: Alzheimer's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 39

Figure 23: Alzheimer's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 40

Figure 24: Alzheimer's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 41

Figure 25: Alzheimer's Disease Market, Spain, Treatment Usage Pattern ('000), 2012–2018 42

Figure 26: Alzheimer's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 43

Figure 27: Alzheimer's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 44

Figure 28: Alzheimer's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 45

Figure 29: Parkinson's Disease Market, Global, Revenue Forecast ($m), 2012–2018 49

Figure 30: Parkinson's Disease Market Global, Treatment Usage Pattern ('000), 2012–2018 50

Figure 31: Parkinson's Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018 51

Figure 32: Parkinson's Disease Market, US, Revenue Forecast ($m), 2012–2018 52

Figure 33: Parkinson's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 53

Figure 34: Parkinson's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 54

Figure 35: Parkinson's Disease Market, UK, Revenue Forecast ($m), 2012–2018 55

Figure 36: Parkinson's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 56

Figure 37: Parkinson's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 57

Figure 38: Parkinson's Disease Market, France, Revenue Forecast ($m), 2012–2018 58

Figure 39: Parkinson's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 59

Figure 40: Parkinson's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 60

Figure 41: Parkinson's Disease Market, Germany, Revenue Forecast ($m), 2012–2018 61

Figure 42: Parkinson's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 62

Figure 43: Parkinson's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 63

Figure 44: Parkinson's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 64

Figure 45: Parkinson's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 65

Figure 46: Parkinson's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 66

Figure 47: Parkinson's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 67

Figure 48: Parkinson's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 68

Figure 49: Parkinson's Disease Market, Spain, Treatment Usage Pattern ('000), 2012–2018 69

Figure 50: Parkinson's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 70

Figure 51: Parkinson's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 71

Figure 52: Parkinson's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 72

Figure 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012–2018 76

Figure 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern ('000), 2012–2018 77

Figure 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012–2018 78

Figure 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012–2018 79

Figure 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012–2018 80

Figure 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern ('000), 2012–2018 81

Figure 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012–2018 82

Figure 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012–2018 83

Figure 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern ('000), 2012–2018 84

Figure 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012–2018 85

Figure 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012–2018 86

Figure 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern ('000), 2012–2018 87

Figure 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012–2018 88

Figure 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012–2018 89

Figure 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern ('000), 2012–2018 90

Figure 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012–2018 91

Figure 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012–2018 92

Figure 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern ('000), 2012–2018 93

Figure 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012–2018 94

Figure 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012–2018 95

Figure 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern ('000), 2012–2018 96

Figure 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012–2018 97

Figure 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012–2018 98

Figure 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern ('000), 2012–2018 99

Figure 77: Huntington's Disease Market, Global, Revenue Forecast ($m), 2012–2018 103

Figure 78: Huntington's Disease Market, Global, Treatment Usage Pattern ('000), 2012–2018 104

Figure 79: Huntington's Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018 105

Figure 80: Huntington's Disease Market, US, Revenue Forecast ($m), 2012–2018 106

Figure 81: Huntington's Disease Market, US, Annual Cost of Therapy ($), 2012–2018 107

Figure 82: Huntington's Disease Market, US, Treatment Usage Pattern ('000), 2012–2018 108

Figure 83: Huntington's Disease Market, UK, Revenue Forecast ($m), 2012–2018 109

Figure 84: Huntington's Disease Market, UK, Annual Cost of Therapy ($), 2012–2018 110

Figure 85: Huntington's Disease Market, UK, Treatment Usage Pattern ('000), 2012–2018 111

Figure 86: Huntington's Disease Market, France, Revenue Forecast ($m), 2012–2018 112

Figure 87: Huntington's Disease Market, France, Annual Cost of Therapy ($), 2012–2018 113

Figure 88: Huntington's Disease Market, France, Treatment Usage Pattern ('000), 2012–2018 114

Figure 89: Huntington's Disease Market, Germany, Revenue Forecast ($m), 2012–2018 115

Figure 90: Huntington's Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018 116

Figure 91: Huntington's Disease Market, Germany, Treatment Usage Pattern ('000), 2012–2018 117

Figure 92: Huntington's Disease Market, Italy, Revenue Forecast ($m), 2012–2018 118

Figure 93: Huntington's Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018 119

Figure 94: Huntington's Disease Market, Italy, Treatment Usage Pattern ('000), 2012–2018 120

Figure 95: Huntington's Disease Market, Spain, Revenue Forecast ($m), 2012–2018 121

Figure 96: Huntington's Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018 122

Figure 97: Huntington's Disease Market, Spain, Treatment Usage Pattern ('000), 2012–2018 123

Figure 98: Huntington's Disease Market, Japan, Revenue Forecast ($m), 2012–2018 124

Figure 99: Huntington's Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018 125

Figure 100: Huntington's Disease Market, Japan, Treatment Usage Pattern ('000), 2012–2018 126

Figure 101: Neurodegenerative Diseases Market, Global, Product Pipeline by Indication (%), 2012 128

Figure 102: Neurodegenerative Diseases Market, Global, Product Pipeline by Phase (%), 2012 128

Figure 103: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004–2012 158

Figure 104: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004–2012 159

Figure 105: Neurodegenerative Diseases Market, Licensing Agreements, 2004–2012 166

Figure 106: Neurodegenerative Diseases Market, Licensing Agreements (%), 2004–2012 166

Figure 107: Neurodegenerative Diseases Market, Co-Development Agreements, 2004–2012 173

Figure 108: Neurodegenerative Diseases Market, Co-Development Agreements (%), 2004–2012 173

Figure 109: GBI Research Market Forecasting Model 183

To order this report:Pathology Industry: Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here